Skip to main content
PLOS ONE logoLink to PLOS ONE
. 2021 Mar 23;16(3):e0248722. doi: 10.1371/journal.pone.0248722

The incidence of acute respiratory infection in Indonesian infants and association with vitamin D deficiency

Vicka Oktaria 1,2,*, Margaret Danchin 1, Rina Triasih 2, Yati Soenarto 2, Julie E Bines 1, Anne-Louise Ponsonby 1, Michael W Clarke 3, Stephen M Graham 1
Editor: Pal Bela Szecsi4
PMCID: PMC7987198  PMID: 33755666

Abstract

Background

Vitamin D deficiency has been associated with acute respiratory infection (ARI) in early life, but this has not been evaluated in Indonesia. We aimed to determine the incidence of ARI in Indonesian infants, and to evaluate the association with vitamin D deficiency.

Methods

From 23 December 2015 to 31 December 2017, we conducted a community-based prospective cohort study in Yogyakarta province. We enrolled 422 pregnant women and followed their infants from birth until 12 months of age for ARI episodes. Vitamin D status was measured at birth and at age six months. We performed Cox proportional hazard regression analysis to evaluate the association between vitamin D deficiency and pneumonia incidence.

Results

At study completion, 95% (400/422) of infants retained with a total of 412 child years of observation (CYO). The incidence of all ARI and of WHO-defined pneumonia was 3.89 (95% CI 3.70–4.08) and 0.25 (95% CI 0.21–0.30) episodes per CYO respectively. Vitamin D deficiency at birth was common (90%, 308/344) and associated with more frequent episodes of ARI non-pneumonia (adjusted odds ratio 4.48, 95% CI:1.04–19.34). Vitamin D status at birth or six months was not associated with subsequent pneumonia incidence, but greater maternal sun exposure during pregnancy was associated with a trend to less frequent ARI and pneumonia in infants.

Conclusion

ARI, pneumonia, and vitamin D deficiency at birth were common in Indonesian infants. Minimising vitamin D deficiency at birth such as by supplementation of mothers or safe sun exposure during pregnancy has the potential to reduce ARI incidence in infants in this setting.

Introduction

Acute respiratory infection (ARI) is the leading cause of disease and death in young children (<5 years) globally [1, 2]. ARI incorporates a wide range of respiratory illnesses from mild to life-threatening, that are classified based on location of infection in relation to the vocal cords into: upper respiratory tract infection (URTI) such as rhinitis, nasopharyngitis, tonsillitis, or epiglottitis; and lower respiratory tract infection (LRTI) such as pneumonia, bronchiolitis or croup [3]. Upper respiratory tract infection (URTI) is a very common outpatient presentation associated with low mortality but significant health systems costs [1, 4]. Lower respiratory tract infection (LRTI), specifically pneumonia, is a major cause of hospitalisation and mortality in young children, with infants (<1 year) at highest risk for death.

Indonesia, along with India, Nigeria, Pakistan, and China, contributes to more than half of the estimated 138 million pneumonia cases in young children globally in 2015 [5]. In the same year, the total number of estimated pneumonia episodes in Indonesian children aged younger than five years old were 3,196,000 episodes (2,447,000 to 3,666,000 episodes), with an incidence rate of ~ 300 cases per 1000 population.(1, 3) The total number of estimated deaths reported in that year was 15,250 deaths (9,900 to 20,124 deaths) [2, 57]. However, prospective community-based cohort studies that measure actual pneumonia incidence are scarce in high-burden, resource-limited settings such as in Indonesia [8]. Data in Indonesian children are drawn either from prospective cohort studies conducted more than a decade ago prior to the implementation of Haemophilus influenzae type b vaccine into the Indonesian national immunisation program in 2013, or from epidemiological modelling studies [2, 9].

The major recognised bacterial pathogens causing pneumonia, influencing global efforts to prevent pneumonia-related deaths through case management and vaccines, have been Streptococcus pneumoniae and Haemophilus influenzae type b (Hib) [2]. Since the Hib vaccine was included in the routine immunisation schedule in 2013, the prevalence of Hib carriage has been shown to decline to 0% compared to 5% as reported in 1998 [10, 11]. With socioeconomic development and the introduction of bacterial conjugate vaccines, the epidemiology is changing with a relatively larger proportion of ARI due to viruses and a lower mortality attributed to ARI [12]. Nonetheless, there remains huge potential for public health interventions that can further reduce the significant incidence and morbidity due to ARI in infants [13].

ARI risk factors in Indonesia are similar to the global population. These include poverty, indoor pollution, suboptimum exclusive breastfeeding and poor nutritional status [5, 14]. Nutritional deficiency, including both macro and micronutrient deficiencies, is common in Indonesian children [15, 16]. The potential of vitamin D to prevent and/or treat ARI in children has been a focus of recent research [1719]. Rickets, the most severe clinical manifestation of vitamin D deficiency, has been reported as common in young children with severe pneumonia in some settings [20]. Subclinical vitamin D deficiency (serum vitamin D <50 nmol/L) is far more common than clinical rickets in young children [2123] and has also been associated with ARI, including increased risk of URTI, LRTI, and LRTI hospitalisation [18, 19, 24]. There is biological plausibility for this association given the immunomodulatory effects of vitamin D deficiency [25]. However, a limited number of studies on vitamin D supplementation in children with ARI have been published to date and evidence of a convincing association with prevention or treatment of outcomes is still lacking [17, 26]. The World Health Organisation (WHO) has called for more research to guide recommendations for the role of vitamin D supplementation to prevent ARIs [27]. A high prevalence of vitamin D deficiency has been reported in children in South East Asia, particularly in newborns [21, 28, 29]. The prevalence of vitamin D deficiency in Indonesia children aged 2–5 years old was 44% and newborns have been reported at high risk of vitamin D deficiency [29, 30].

We aimed to determine ARI incidence in a cohort of Indonesian infants and the association between vitamin D deficiency at birth and at six months of age with the development of ARI, including of WHO-defined pneumonia. We also evaluated the risk factors for the first episode of pneumonia.

Materials and methods

A prospective birth cohort study (the Indonesian Pneumonia and vitamin D study—IPAD study) was conducted in nine Primary Healthcare Centres (Jetis, Tegalrejo, Gedongtengen, Gondokusuman 2, Mantrijeron, Gondomanan, Wates, Sentolo, Pengasih 1) and five private practice clinics (Sri Suharti, Suwarti, Sulalita, Sri Suyantiningsih, and Sri Esthini) located in two districts in Yogyakarta province, Indonesia. Yogyakarta province is populated by approximately 3.7 million people (1.4%, 3.7/255 million people of the Indonesian population) with the two study districts, Kota Yogyakarta and Kulon Progo, each having approximately 400,000 people.

Study procedures

An attending study midwife or doctor recruited mothers during the third trimester of pregnancy at routine antenatal visits. Inclusion criteria included expected delivery in one of the study sites without intention to leave the area within 12 months. Parents who did not provide written informed consent for their child’s participation or who did not have phone access were not included. Informed consent was obtained prior to delivery and included the intention to actively follow infants for 12 months, and to collect cord blood at delivery and a venous blood sample at six months of age. Written informed consent was reaffirmed after delivery of a live birth.

Active and passive surveillances were undertaken to capture ARI episodes during the 12-month period of observation. Ten routine follow-up visits within the child’s first year, included seven face-to-face visits at ages 1, 2, 3, 4, 6, 9, and 12 months and three phone interviews at ages 5, 7, and 10 months. Routine two-weekly calls were conducted to complement the monthly data collection. At the first visit, we interviewed parents using a structured questionnaire (S1 File) to ascertain demographic data, pregnancy, maternal, and infant sun behaviour, and birth history. During each follow-up visit or routine two-weekly calls, parents were specifically asked about the occurrence of any respiratory symptoms since the previous visit/call. Parents were encouraged to contact the study team within 24 hours of the onset of respiratory symptoms to seek medical advice. A home visit by the study team was performed if the infants reported cough for more than three days to obtain the respiratory rate, assess the severity of the ARI episode, and provide appropriate medical advice regarding the need for referral to the study Primary Healthcare Centre to receive antibiotics for possible pneumonia, according to WHO guidelines [31]. Phone follow-up for ARI episodes were conducted at 3-day intervals until the symptom resolution. Routine medical chart review was conducted at the study sites by the study team. A study booklet was provided to all mothers to record information on any medical services sought for the infant. If infants required hospitalisation for respiratory infections in non-study hospitals, with the parent’s permission, the hospital discharge letter was accessed to record diagnosis, clinical management, and outcome.

All study team members completed mandatory training for identification of the signs and case management of pneumonia as per the current WHO classification [20]. Criteria for WHO-defined “pneumonia” are cough with fast breathing or chest indrawing, without danger signs (i.e. cyanosis, hypoxia, unable to drink, or seizure); for “severe pneumonia” with any danger sign present [31]. ARI non-pneumonia episode was defined for respiratory symptoms (including runny nose, fever, sore throat and/or cough) without fast breathing or chest indrawing. A new episode of ARI was defined if there were seven symptom-free days since the previous episode, and of pneumonia after one symptom-free month after the last episode of pneumonia. ARI-received antibiotics was the term used when parents reported that infants had ARI-non-pneumonia diagnosed after antibiotics had been administered, or any ARI with antibiotics administration but information from the medical record or parental reporting was incomplete/insufficient for the study team to classify ARI as pneumonia or non-pneumonia. Maternal sun-exposure during pregnancy or cumulative infant sun-exposure was defined as cumulative composite estimate UVR which was a product of time spent outdoors multiplied by the ambient ultraviolet B during the period of time (per 100 mW/m2/nm/hour).

Sera from cord blood and venous blood were assayed at Metabolomics Australia, Centre for Microscopy, Characterisation, and Analysis, University of Western Australia. The total serum 25-hydroxyvitamin D concentrations were measured using liquid chromatography-tandem mass spectrometry, the current gold standard for vitamin D measurement, which has shown excellent agreement with Center for Disease Control and Prevention’s 25-hydroxyvitamin D inaugural Vitamin D standardisation program (r2 = 0.99) [32]. The analytical sensitivity (or limit of detection) and the functional sensitivity (or limit of quantitation) of the assay for 25-hydroxyvitamin D3 is 0.5 nM and 2 nmol/L respectively.

Commercial quality controls are assayed at the beginning and end of each batch, with intra-assay Coefficient of variability’s (CV’s) for all three metabolites <5%, with inter-assay CV’s being <10%. Internal standard peak areas are monitored for each batch and are <10% within each run. We defined vitamin D deficiency as a serum 25-hydroxyvitamin D3 level of <50 nmol/L.

Statistical analysis

All analyses were performed using STATA 15 (Stata Corp, College Station, TX). We aimed to recruit at least 250 infants over the 12-month study period. Allowing for a 10% refusal rate and 10% loss to follow-up prior to the first post-natal visit, this enabled the description of the incidence of pneumonia to within 4–6% based on an incidence rate of 0.1 to 0.5 per person-year (primary objective) based on a two-sided 95% confidence interval.

The time period of observation for each infant was determined as the period in days from the date of birth until the date of the last contact made (final follow-up, prior to lost to follow-up or date of death) to calculate child years of observation (CYO). Cox proportional hazard regression model of survival analysis was performed to explore the association between vitamin D status at birth with the hazard rate of having a first episode of pneumonia in the first and second six months, and the association between vitamin D status at six months and the hazard rate of having the first episode of pneumonia when infants were aged between 6–12 months. Linear and logistic regression were performed to explore the association between vitamin D status and the total number of ARI episodes. Confounding was determined: if the difference between the Odd Ratio (OR) or Hazard Ratio (HR) in the univariate and multivariate models changed by more than 10% or based on a priori knowledge. A sensitivity analysis using a lower cut off vitamin D level of <25 nmol/L (severe vitamin D deficiency) and a higher cut off vitamin D level of < 75 nmol/L was performed. A p-value <0.05 was considered statistically significant.

Ethics

We obtained ethical approval for the study from the Medical and Health Research Ethics Committee of Universitas Gadjah Mada Yogyakarta, Indonesia (ethics approval number KE/FK/935/EC/2015, July 2015) and the University of Melbourne Human Research Committee (ethics approval number 1544817, October 2015).

Results

Between 23 December 2015 and 31 December 2017, we recruited 422 infants with 95% (400/422) of infants retained for the full twelve months of follow-up. Of recruited infants, 82% (348/422) had cord blood samples and 60% (255/422) had venous blood samples at six months of age (Fig 1).

Fig 1. A flow chart depicts infants flow and vitamin D sample availability.

Fig 1

*74 cord blood samples were not collected as the mother was referred to hospital due to complication or post-dates (n = 47); or midwife missed the blood collection (n = 27); 95 Venous blood samples were not collected: no cord blood samples (n = 60); lost to follow-up before age turned to 6 months old (n = 1; parents refused for blood collection (n = 10; parent refused, LTFU (n = 2), venous blood was collected at ≥7 months of age (n = 22); 2 Venous blood without cord blood samples at birth were collected due to infants developed pneumonia later after birth; IUFD: Intra Uterine Fetal Death.

The demographics characteristics of infants with vitamin D samples at birth and six months of age were representative of the entire cohort (Table 1). The mean serum vitamin D concentrations at birth and at six months were 30 nmol/L ± 14 nmol/L and 77 ± 26 nmol/L, respectively. The prevalence of vitamin D deficiency was 90% (308/344) at birth and 13% (33/255) at six months (± 4 weeks).

Table 1. Demographic characteristics and ARI outcomes of infants by vitamin D sample availability.

Entire cohort
N = 422
N (%)
Group 1:
Infants with cord blood
N = 344
(82% of total cohort)
Group 2:
Infants with venous blood at 6 months of age
N = 255
(60% of total cohort)
Demographic characteristics
Male infants–n (%) 209 (50%) 168 (49%) 128 (50%)
Birth weight in grams–(median, IQR) 3100 (2900, 3400) 3100 (2900, 3350) 3100 (2900, 3400)
Premature birth 8 (2%) 6 (2%) 5 (2%)
Low birth weight 17 (4%) 14 (4%) 12 (5%)
Maternal age in years–(median, IQR) 29 (24, 33) 29 (24, 33) 29 (25, 33)
Paternal smoking–n (%) 204 (49%) 169 (49%) 130 (51%)
Number of people living with infants (median, IQR), 4 (3–5) 4 (3–5) 4 (3–5)
Family income per month–n (%)
< IDR 1000k 207 (49%) 175 (51%) 140 (55%)
IDR 1000k – 5000k 200 (48%) 156 (46%) 107 (42%)
IDR > 5000k 14 (3%) 12 (4%) 8 (3%)
Exclusive breastfeeding–n (%) 228 (56%) 191 (58%) 155 (61%)
ARI outcomes
Total ARI episodes,—(mean ± SD) 3.80 (± 2) 3.69 (± 2) 3.96 (± 2)
Infants with pneumonia–n (%) 89 (21%) 76 (22%) 66 (26%)

An analysis of the determinants of vitamin D deficiency at birth and at 6 months has been reported elsewhere [29]. Mothers who spent two hours or more per day outside were less likely to have a newborn with vitamin D deficiency compared to those who spent only 15 minutes or less in the sun [29].

Overall, there were 1,601 ARI episodes identified within 412 CYO. The WHO criteria for pneumonia and severe pneumonia were met for 96 and 7 of the ARI episodes respectively, and 8.7% (9/103) of the pneumonia episodes were hospitalised. Almost all (96%) infants had at least one episode of ARI non-pneumonia (Table 2). The incidence rate for all ARI was 3.89 (95% CI: 3.70–4.08) and for pneumonia was 0.25 (95% CI: 0.21–0.30) episodes per CYO (Table 3). The highest incidence rate for all ARI and pneumonia was in the 9 to <12-month age group and the lowest incidence rate was in infants <3 months of age. The duration of illness to complete symptom resolution for non-pneumonia and pneumonia ARI was 7 days (4–9 days) and 15 days (11–26 days), respectively. Of pneumonia episodes, 6.8% (7/103) presented with wheezing and 2.9% (3/103) were hypoxemic.

Table 2. The total number of ARI episodes in the study cohort.

WHO-defined pneumonia No. infants (%)
0 episode 332 (79%)
1 episode 76 (18%)
2 episodes 12 (2·5%)
3 episodes 1 (0·5%)
ARI non-pneumonia No. infants (%)
Median (IQR) 5 (3–6)
0 episode 23 (5%)
1 episode 41(10%)
2 episodes 59 (14%)
3 episodes 89 (21%)
4 episodes 80 (19%)
5 episodes 63 (15%)
6 episodes 39 (9%)
7 episodes 15 (4%)
8 episodes 10 (2%)
9 episodes 2 (1%)

ARI non-pneumonia defined respiratory symptoms such as cough but without fast breathing or chest indrawing, including rhinitis, rhino pharyngitis but the diagnosis was not further specified.

Table 3. The incidence of ARI by age.

Incidence rates episodes per CYO (95% Cis)
Incidence rates per CYO (95% Cis)
Total CYO ALL ARI ARI non-pneumonia ARI received antibiotics WHO-defined pneumonia WHO-defined severe pneumonia Hospitalised pneumonia
All 412 3.89 (3.70–4.08) 3.63 (3.46–3.83) 0.62 (0.55–0.70) 0.25 (0.21–0.30) 0.02 (0.01–0.04) 0.02 (0.01–0.04)
Per 3 months age group
0–2 months 104 1.87 (1.62–2.14) 1.78 (1.54–2.06) 0.14 (0.08–0.23) 0.08 (0.04–0.15) 0.01 (0.001–0.07) 0.02 (0.005–0.08)
3–5 months 102 3.94 (3.57–4.34) 3.68 (3.33–4.07) 0.32 (0.23–0.46) 0.26 (0.17–0.38) n/a 0.02 (0.005–0.08)
6–8 months 101 4.53 (4.13–4.97) 4.25 (3.87–4.67) 0.82 (0.66–1.01) 0.28 (0.19–0.40) 0.03 (0.01–0.09) 0.05 (0.02–0.12)
9–<12 months 105 5.22 (4.81–5.68) 4.84 (4.44–5.28) 1.19 (1.00–1.41) 0.39 (0.29–0.53) 0.03 (0.01–0.09) n/a
WHO age group
< 2 months 70 1.70 (1.42–2.03) 1.61 (1.34–1.94) 0.17 (0.10–0.30) 0.09 (0.04–0.19) 0.01(0.002–0.10) 0.03 (0.007–0.12)
2–<12 months 342 4.33 (4.12–4.56) 4.05 (3.84–4.27) 0.71 (0.62–0.80) 0.28 (0.23–0.35) 0.02 (0.008–0.04) 0.02 (0.009–0.04)

CYO = child year observation.

ARI-received antibiotics was the term used when parents reported that infants had ARI-non-pneumonia diagnosed (above classification) after antibiotics had been administered, or any ARI with antibiotics administration but information from medical record or parental reporting was incomplete/insufficient for study team to classify ARI as pneumonia or non-pneumonia.

The incidence rate for the first episode of pneumonia within the first and second six months was not different between those with vitamin D deficiency and vitamin D sufficiency at birth (level ≥ 50 nmol/L) (Table 4). Similarly, vitamin D status at six months of age was not associated with the incidence rate of first pneumonia episode that occurred between six and 12 months of age (Table 5). Kaplan-Meier curves of pneumonia-free survival by (a) vitamin D status at birth and by (b) vitamin D status at 6 months of age are plotted in Fig 2. A sensitivity analysis using a lower cut off vitamin D level of <25 nmol/L did not alter the results. Male-sex and passive exposure to paternal smokers were associated with a higher rate of pneumonia. Maternal sun exposure during pregnancy, but not infant sun exposure from birth to six months of age, was associated with a reduced risk of pneumonia (Table 5) and less frequent ARI non-pneumonia during infancy (adjusted OR 0.78; 95% CI: 0.60–0.98, result not shown in the table). There were weak correlations between maternal and infant sun exposure: Spearman’s correlation coefficients r 0.12, P 0.02 for weekday and weekend exposure.

Table 4. Hazard rates and 95% confidence intervals for possible risk factors associated with first episode of pneumonia during infancy by age group.

Pneumonia episode at 0–5 months Pneumonia episode at 6–11 months Pneumonia episode during infancy
Cases CYO Hazard Rate (95% CI) Cases CYO Hazard rate (95% CI) Cases CYO Hazard rate (95% CI)
Sex
Female 9 98 0.09 (0.05–0.18) 22 93 0.24 (0.15–0.36) 31 190 0.16 (0.11–0.23)
Male 23 96 0.24 (0.16–0.36) 35 82 0.43 (0.31–0.59) 58 178 0.33 (0.25–0.42)
Prematurity
At term 30 188 0.16 (0.11–0.23) 54 169 0.32 (0.25–0.42) 84 356 0.24 (0.19–0.29)
Less than 37 weeks 0 0 0 3 4 0.74 (0.24–2.30) 3 8 0.37 (0.12–1.16)
Low birth weight
Normal 30 182 0.17 (0.12–0.24) 56 163 0.34 (0.27–0.45) 86 345 0.24 (0.20–0.30)
Low 0 8·5 0 1 9 0.11 (0.02–0.80) 1 17 0.58 (0.01–0.41)
EBF
Yes 20 107 0.19 (0.12–0.29) 27 99 0.27 (0.19–0.40) 47 207 0.23 (0.17–0.30)
No 12 84 0.14 (0.08–0.25) 30 75 0.40 (0.28–0.57) 42 160 0.26 (0.19–0.36)
Number of people living in the house
< 7 people 24 171 0.14 (0.09–0.21) 50 156 0.32 (0.24–0.42) 74 327 0.23 (0.18–0.28)
≥ 7 people 8 23 0.35 (0.17–0.69) 7 19 0.38 (0.18–0.79) 15 42 0.36 (0.22–0.60)
Mother sun exposure for the entire pregnancy
Weekday
(per 100 mW/m2/nm/hour). Interquartile range
Quartile 1 (91–174) 9 46 0.20 (0.10–0.38) 19 39 0.49 (0.31–0.76) 28 85 0.33 (0.23–0.48)
Quartile 2 (183–342) 6 47 0.13 (0.06–0.29) 16 43 0.37 (0.23–0.61) 22 90 0.25 (0.16–0.37)
Quartile 3 (363–379) 10 42 0.24 (0.13–0.44) 12 36 0.33 (0.19–0.58) 22 78 0.28 (0.19–0.43)
Quartile 4 (743–1134) 5 45 0.11 (0.05–0.27) 9 43 0.21 (0.11–0.41) 14 88 0.16 (0.09–0.27)
Weekend
(per 100 mW/m2/nm/hour). Interquartile range
Quartile 1 (91–174) 9 50 0.18 (0.09–0.35) 20 43 0.47 (0.30–0.72) 29 92 0.31 (0.22–0.45)
Quartile 2 (183–192) 6 44 0.14 (0.06–0.30) 13 41 0.31 (0.18–0.54) 19 86 0.22 (0.14–0.35)
Quartile 3 (356–378) 9 47 0.19 (0.10–0.37) 16 41 0.39 (0.24–0.64) 25 88 0.29 (0.19–0.42)
Quartile 4 (726–1134) 6 49 0.12 (0.05–0.27) 8 46 0.17 (0.09–0.35) 14 96 0.15 (0.09–0.25)
Infant cumulative sun exposure during 0–5 months of agea
Weekday
(per 100 mW/m2/nm/hour). Interquartile range
Quartile 1 (196–256) NA 14 44 0.32 (0.19–0.53) NA
Quartile 2 (303–350) 16 42 0.38 (0.23–0.63)
Quartile 3 (394–459) 13 43 0.30 (0.18–0.52)
Quartile 4 (559–806) 12 41 0.29 (0.17–0.51)
Weekend
(per 100 mW/m2/nm/hour). Interquartile range
Quartile 1 (200–260) NA 16 40 0.40 (0.25–0.66) NA
Quartile 2 (303–351) 12 40 0.30 (0.17–0.54)
Quartile 3 (396–465) 13 39 0.33 (0.19–0.57)
Quartile 4 (567–835) 11 38 0.29 (0.16–0.52)
Father smokes everyday
No 12 94 0.13 (0.07–0.22) 22 88 0.25 (0.17–0.38) 34 182 0.19 (0.13–0.26)
Yes 20 99 0.20 (0.13–0.31) 34 87 0.39 (0.28–0.55) 54 186 0.29 (0.22–0.37)
BCG vaccination
Yes 31 184 0.17 (0.12–0.24) 55 167 0.33 (0.25–0.43) 86 351 0.25 (0.20–0.30)
No 1 10 0.10 (0.01–0.71) 2 8 0.25 (0.06–1.00) 3 18 0.17 (0.05–0.53)
Cord blood vitamin D status
≥ 50 nmol/L 4 26 0.25 (0.09–0.66) 5 14 0.36 (0.15–0.86) 9 30 0.30 (0.16–0.57)
< 50 nmol/L 25 140 0.18 (0.12–0.26) 42 126 0.33 (0.25–0.45) 67 266 0.25 (0.20–0.32)
Vitamin D status at 6 months
≥ 50 nmol/L NA 32 91 0.35 (0.25–0.50) NA
< 50 nmol/L 7 14 0.51 (0.24–1.07)

Cases = number of infants had first episode of pneumonia.

CYO = child year of observation.

EBF = Exclusive breastfeeding.

Low birth weight (below 2500 grams) versus normal birth weight (2500–4000 grams).

Maternal sun exposure during pregnancy was defined as cumulative composite estimate UVR exposure during pregnancy which was product of time spent outdoors multiplied by the ambient ultraviolet B during the period of time (per 100 mW/m2/nm/hour).

Maternal cumulative composite weekday: quartile 1 (91–174 per 100 mW/m2/nm/hour); quartile 2 (183–342 per 100 mW/m2/nm/hour); quartile 3 (363–379 per 100 mW/m2/nm/hour); and quartile 4 (743–1134 per 100 mW/m2/nm/hour).

Maternal cumulative composite weekend: quartile 1 (91–174 per 100 mW/m2/nm/hour); quartile 2 (183–192 per 100 mW/m2/nm/hour); quartile 3 (356–378 per 100 mW/m2/nm/hour); and quartile 4 (726–1134 per 100 mW/m2/nm/hour).

Infant cumulative composite weekday: quartile 1 (196–256 per 100 mW/m2/nm/hour); quartile 2 (303–350 per 100 mW/m2/nm/hour); quartile 3 (394–459 per 100 mW/m2/nm/hour); and quartile 4 (559–806 per 100 mW/m2/nm/hour).

Infant cumulative composite weekend: quartile 1 (200–260 per 100 mW/m2/nm/hour); quartile 2 (303–351 per 100 mW/m2/nm/hour); quartile 3 (396–465 per 100 mW/m2/nm/hour); and quartile 4 (567–835 per 100 mW/m2/nm/hour).

NA = not applicable.

a The association between infant cumulative sun exposure and first episode of pneumonia was calculated on the basis of the temporal sequence of exposure before outcome which was not applicable to the association between infant cumulative sun exposure between 0–6 months of age and first episode of pneumonia between 0–6 months of age.

Table 5. Cox proportional hazard ratio estimates and 95% confidence intervals for possible risk factors associated with first episode of pneumonia by age group in univariate and multivariate model.

Hazard Ratio (95% CI)
7 Pneumonia onset Pneumonia onset Pneumonia onset in the
0–5 months 6–11 months first postnatal year
Male- vs. female-sex a Univariate 2.63 (1.21–5.68) 1.79 (1.05–3.06) 2.04 (1.32–3.15)
P 0.01 P 0.01 P 0.01
Multivariate 2.91 (1.28–6.60) 1.82 (1.06–3.15) 2.12 (1.35–3.33)
P 0.01 P 0.03 P 0.001
Non EBF vs. EBFb Univariate 0.76 (0.37–1.55) 1.50 (0.89–2.52) 1.18 (0.78–1.79)
P 0.45 P 0.13 P 0.44
Multivariate 0.59 (0.27–1.27) 1.44 (0.85–2.45) 1.07 (0.70–1.65)
P 0.18 P 0.18 P 0.75
≥ 7 people vs. < 7 people lived in the housec Univariate 2.51 (1.13–5.60) 1.17 (0.53–2.59) 1.63 (0.94–2.85)
P 0.02 P 0.69 P 0.08
Multivariate 2.64 (1.17–5.96) 1.13 (0.51–2.51) 1.61 (0.92–2.81)
P 0.02 P 0.76 P 0.10
Father smokes everyday vs. non-smoker fatherd Univariate 1.58 (0.77–3.24) 1.56 (0.91–2.67) 1.57 (1.02–2.41)
P 0.21 P 0.11 P 0.04
Multivariate 1.87 (0.87–3.99) 1.59 (0.92–2.73) 1.67 (1.07–2.60)
P 0.11 P 0.10 P 0.02
Cord blood vitamin D status < 50 nmol/L vs. ≥ 50 nmol/Le Univariate 0.71 (0.25–2.04) 0.91 (0.36–2.30) 0.82 (0.41–1.65)
P 0.53 P 0.84 P 0.58
Multivariate 0.50 (0.17–1.47) 0.84 (0.33–2.13) 0.71 (0.35–1.44)
P 0.21 P 0.71 P 0.34
Vitamin D status at 6 months < 50 nmol/L vs. ≥ 50 nmol/Le Univariate NA 1.53 (0.67–3.47) NA
P 0.31
Multivariate 1.49 (0.63–3.52)
P 0.36
Mother sun exposure for the entire pregnancyf
 • Weekday
  ◦ Q2 vs. Q1 Univariate 0.64 (0.23–1.81) 0.75 (0.39–1.47) 0.72 (0.41–1.26)
P 0.40 P 0.41 P 0.25
  ◦ Q3 vs. Q1 Univariate 1.21 (0.49–2.97) 0.69 (0.33–1.41) 0.85 (0.49–1.49)
P 0.68 P 0.31 P 0.58
  ◦ Q4 vs. Q1 Univariate 0.56 (0.19–1.66) 0.44 (0.20–0.97) 0.48 (0.25–0.90)
P 0.29 P 0.04 P 0.02
Trend per 1 increase of quartile Univariate 0.91 (0.66–1.25) 0.78 (0.61–0.99) 0.82 (0.68–1.00)
P 0.57 P 0.04 P 0.05
  ◦ Q2 vs. Q1 Multivariate 0.62 (0.22–1.74) 0.75 (0.38–1.48) 0.70 (0.40–1.24)
P 0.36 P 0.40 P 0.22
  ◦ Q3 vs. Q1 Multivariate 1.27 (0.51–3.15) 0.68 (0.33–1.42) 0.85 (0.48–1.49)
P 0.61 P 0.31 P 0.57
  ◦ Q4 vs. Q1 Multivariate 0.55 (0.18–1.65) 0.45 (0.20–1.00) 0.47 (0.25–0.90)
P 0.28 P 0.05 P 0.02
Trend per 1 increase of quartile Multivariate 0.91 (0.66–1.26) 0.78 (0.61–1.00) 0.82 (0.68–1.00)
P 0.58 P 0.05 P 0.05
 • Weekend
  ◦ Q2 vs. Q1 Univariate 0.74 (0.26–2.09) 0.65 (0.32–1.31) 0.68 (0.38–1.22)
P 0.57 P 0.23 P 0.19
  ◦ Q3 vs. Q1 Univariate 1.06 (0.42–2.67) 0.84 (0.44–1.62) 0.91 (0.53–1.55)
P 0.90 P 0.61 P 0.73
  ◦ Q4 vs. Q1 Univariate 0.67 (0.24–1.88) 0.37 (0.16–0.84) 0.46 (0.24–0.87)
P 0.45 P 0.02 P 0.02
Trend per 1 increase of quartile Univariate 0.92 (0.67–1.26) 0.78 (0.62–0.99) 0.83 (0.69–1.00)
P 0.62 P 0.05 P 0.05
  ◦ Q2 vs. Q1 Multivariate 0.73 (0.26–2.06) 0.63 (0.31–1.29) 0.66 (0.37–1.19)
P 0.55 P 0.21 P 0.16
  ◦ Q3 vs. Q1 Multivariate 1.15 (0.45–2.92) 0.88 (0.45–1.71) 0.94 (0.55–1.61)
P 0.77 P 0.70 P 0.82
  ◦ Q4 vs. Q1 Multivariate 0.70 (0.25–1.97) 0.37 (0.16–0.85) 0.46 (0.24–0.87)
P 0.50 P 0.02 P 0.02
Trend per 1 increase of quartile Multivariate 0.94 (0.69–1.30) 0.79 (0.62–1.00) 0.83 (0.69–1.01)
P 0.72 P 0.05 P 0.06
Infant cumulative sun exposure between 0–6 months of agef,g
 • Weekday NA NA
  ◦ Q2 vs. Q1 Univariate 1.18 (0.58–2.43)
P 0.65
  ◦ Q3 vs. Q1 Univariate 0.94 (0.44–2.00)
P 0.87
  ◦ Q4 vs. Q1 Univariate 0.93 (0.43–2.00)
P 0.85
Trend per 1 increase of quartile Univariate 0.96 (0.75–1.21)
P 0.71
  ◦ Q2 vs. Q1 Multivariate 1.16 (0.57–2.39)
P 0.68
  ◦ Q3 vs. Q1 Multivariate 0.88 (0.40–1.91)
P 0.74
  ◦ Q4 vs. Q1 Multivariate 0.90 (0.42–1.96)
P 0.80
Trend per 1 increase of quartile Multivariate 0.94 (0.74–1.20)
P 0.64
 • Weekend
  ◦ Q2 vs. Q1 Univariate 0.73 (0.34–1.55)
P 0.41
  ◦ Q3 vs. Q1 Univariate 0.80 (0.38–1.66)
P 0.55
  ◦ Q4 vs. Q1 Univariate 0.72 (0.33–1.54)
P 0.39
Trend per 1 increase of quartile Univariate 0.91 (0.71–1.16)
P 0.44
  ◦ Q2 vs. Q1 Multivariate 0.71 (0.33–1.51)
P 0.38
  ◦ Q3 vs. Q1 Multivariate 0.72 (0.33–1.55)
P 0.40
  ◦ Q4 vs. Q1 Multivariate 0.72 (0.33–1.54)
P 0.39
Trend per 1 increase of quartile Multivariate 0.90 (0.70–1.15)
P 0.40

a Adjusted for paternal smoking, overcrowded, low birth weight and EBF.

b Adjusted for paternal smoking, overcrowded, and low birth weight.

c Adjusted for paternal smoking, low birth weight, and EBF.

d Adjusted for baby sex, overcrowded, EBF, and low birth weight.

e Adjusted for birth weight, EBF, paternal smoking, crowding, infants skin type, and month of blood collection.

f Adjusted for paternal smoking, overcrowded, and EBF.

Maternal sun exposure during pregnancy was defined as cumulative composite estimate UVR exposure during pregnancy which was product of time spent outdoors multiplied by the ambient ultraviolet B during the period of time (per 100 mW/m2/nm/hour).

Maternal cumulative composite weekday: quartile 1 (91–174 per 100 mW/m2/nm/hour); quartile 2 (183–342 per 100 mW/m2/nm/hour); quartile 3 (363–379 per 100 mW/m2/nm/hour); and quartile 4 (743–1134 per 100 mW/m2/nm/hour).

Maternal cumulative composite weekend: quartile 1 (91–174 per 100 mW/m2/nm/hour); quartile 2 (183–192 per 100 mW/m2/nm/hour); quartile 3 (356–378 per 100 mW/m2/nm/hour); and quartile 4 (726–1134 per 100 mW/m2/nm/hour).

Infant cumulative composite weekday: quartile 1 (196–256 per 100 mW/m2/nm/hour); quartile 2 (303–350 per 100 mW/m2/nm/hour); quartile 3 (394–459 per 100 mW/m2/nm/hour); and quartile 4 (559–806 per 100 mW/m2/nm/hour).

Infant cumulative composite weekend: quartile 1 (200–260 per 100 mW/m2/nm/hour); quartile 2 (303–351 per 100 mW/m2/nm/hour); quartile 3 (396–465 per 100 mW/m2/nm/hour); and quartile 4 (567–835 per 100 mW/m2/nm/hour).

NA = not applicable.

g The association between infant cumulative sun exposure and first episode of pneumonia was calculated on the basis of the temporal sequence of exposure before outcome which was not applicable to the association between infant cumulative sun exposure between 0–6 months of age and first episode of pneumonia between 0–6 months of age.

Fig 2. Time to develop first episode of pneumonia by vitamin D status at birth and 6 months of age.

Fig 2

(a) Kaplan-Meier survival curve of the first episodes of pneumonia between birth to 12 months of age by vitamin D status at birth. (b) Kaplan-Meier survival curve of the first episodes of pneumonia between 6 to 12 months of age by vitamin D status at six months of age.

The risk of having six or more episodes of ARI non-pneumonia was higher in infants with vitamin D deficiency at birth, even after adjustment for paternal smoking status, low birth weight, overcrowding household, and exclusive breastfeeding status (adjusted OR 4.48; 95% CI: 1.04–19.34, P 0.04). Other risk factors for having one additional episode of non-pneumonia ARI were household crowding (adjusted beta-coefficient 0.12, 95% CI: 0.0–0.23 per additional one person); and preterm born (adjusted beta-coefficient 1.55, 95% CI: 0.23–2.88).

Discussion

We report a high incidence of ARI and pneumonia in Indonesian infants. One in four had an episode of pneumonia in the first year of life, consistent with recent estimates in low- and middle-income countries [5, 33]. Vitamin D deficiency at birth was associated with more frequent episodes of non-pneumonia ARI but not with pneumonia incidence or severity.

The incidence of pneumonia of 0.25 episodes per CYO in our study is comparable to other studies in similar settings. A study in Indonesian infants done nearly two decades ago prior to implementation of the Hib vaccine recorded 0.21 pneumonia episodes per CYO using only passive surveillance [34]. A recent South African birth cohort study of 697 newborns that used active surveillance similar to our study reported 0.27 (95% CI 0.23–0.32) pneumonia episodes during infancy [34, 35]. The reported incidence of all ARI differs more widely. A birth cohort study of 2459 newborns from Vietnam in 2010 that used similar surveillance methods, included urban and semi-rural settings and had a comparable risk factor profile to our study reported fewer episodes of ARI (0.5–2 per CYO) by 12 months of age, but also reported a lower incidence of ARI in infants less than six months of age compared to older infants [33]. Comparisons between studies are often challenging to interpret given that the differences in time periods or epidemiological settings are likely to affect a range of risk factors for ARI in infants which strongly affect the incidence of ARI in the settings.

Known risk factors for pneumonia of male-sex and passive smoking exposure were confirmed in our cohort, consistent with previous studies [35, 36]. Vitamin D deficiency was common at birth or at six months of age but was not associated with subsequent incidence or severity of pneumonia. A recent study from Bangladesh also reported no association between vitamin D status at birth or in infancy and the subsequent development of pneumonia or LRTI [37]. In contrast, an association was reported in a smaller study of young children in Saudi Arabia (adjusted OR 1.08, 95% CI: 1.05–1.10, P <0.001), but this was a retrospective study with passive case-ascertainment that only collected data at the end of the follow-up period requiring medical record review [19]. Active case-ascertainment with frequent follow-up was a strength of our study to reduce the risk of recall bias and misclassification [8, 38]. Large variations in the methodological approaches in observational studies that have previously evaluated the association between vitamin D deficiency and ARI, including pneumonia, challenges the interpretation of study results [19, 3740].

Vitamin D deficiency at birth was associated with higher frequency, i.e. six or more episodes, of URTI. However, the incidence of ARI was highest after 6 months of age when the prevalence of vitamin D deficiency was much lower when compared to that observed at birth. A major limitation of interpretation of findings of an association between vitamin D deficiency and disease incidence from observational cohort studies such as our study is the potential for confounding, especially for ARI which has a wide range of potential aetiologies and epidemiological risk factors. Randomised, placebo-controlled vitamin D supplementation trials in populations with a high prevalence of vitamin D deficiency are likely to provide stronger evidence of association if it exists while also assessing the potential benefit for an intervention. Our finding is consistent with findings from a meta-analysis in a wider age range (birth to 95 years of age) that reported that vitamin D supplementation prevented at least one episode of unspecified ARI (adjusted OR 0.88, 95% CI: 0.81–0.96) but not LRTI (adjusted OR 0.96, 95% CI 0.83–1.10) [41]. Two RCTs conducted in infants and young children in Afghanistan reported that a bolus dose of 100,000 U vitamin D prevented recurrence of pneumonia within 90 days after hospitalisation but did not prevent pneumonia in healthy infants [42, 43]. There is a broad hierarchy of ARI outcomes and interventional doses in the published RCTs that might contribute to the variation in findings [4446]. Evaluation of the impact of low-dose daily or weekly vitamin D supplementation on severe pneumonia in children with profound deficiency has been recommended [41, 47].

Our study showed that a combination of more time spent outdoors with ambient UVB during pregnancy was associated with a reduced risk of pneumonia during infancy. Safe sun exposure practice with repeated low-dose summer sunlight has been associated with vitamin D sufficiency without causing significant DNA damage [48]. Accordingly, native populations in sun-abundant countries such as Indonesia where the majority of skin types range from medium to dark brown could benefit from sunlight but the optimum and safe duration and time of the day under the sun need further elucidation.

It is biologically plausible that vitamin D deficiency may be associated with susceptibility to respiratory infection. Laboratory studies demonstrate that vitamin D plays a direct role in innate immune responses regulating the expression of human antimicrobial peptides (cathelicidin and human beta-defensin 2) for pathogen elimination and reduction of viral replication while in the adaptive immune system, vitamin D suppresses lymphocytes T cells expression to further avoid immune pathology that can injure the lung tissues [25, 49]. However, to what extent the immunomodulatory roles of vitamin D influence the clinical manifestation and severity of respiratory diseases remain uncertain with ongoing controversy about the possible effect of vitamin D on ARI and the potential clinical and public health impact [50].

The strengths of our study include the use of active and passive ARI surveillance with a short assessment period and the use of the standardised WHO case definition for the diagnosis of pneumonia. This has been lacking in previous cohort studies examining an association between vitamin D and ARI. Despite careful, frequent, and thorough case-ascertainment, it is possible that we may have missed some pneumonia episodes and capture less severe cases. If missed episodes occurred it is likely that these would have been random, and independent of the infants’ vitamin D status.

Conclusion

ARI and pneumonia were common in this large cohort of Indonesian infants, among whom vitamin D deficiency was highly prevalent at birth. Vitamin D deficiency was associated with the incidence of ARI but not of pneumonia in the first year of life. Minimising vitamin D deficiency for infants in this setting has potential benefits to reduce ARI incidence and ARI-related healthcare utilisation, which needs to be determined in a therapeutic trial.

Supporting information

S1 File. Study questionnaire and case report files.

(PDF)

Acknowledgments

We thank all infants and parents who participated to this study, all study site staffs from Puskesmas, midwife private practice, health office (Dinas kesehatan kota Yogyakarta and Kulon Progo), and district hospitals in Kota Yogyakarta and Kulon Progo who helped with the study recruitment. Lastly, we especially thank all IPADS research assistants who assisted with data collection and study conduct.

Abbreviations

ARI

Acute respiratory infection

CYO

Child years of observation

EBF

Exclusive breastfeeding

HR

Hazard Ratio

IUFD

Intra Uterine Fetal Death

LRTI

Lower Respiratory Tract Infections

OR

Odd Ratio

RCT

Randomised Controlled Trial

UVB

Ultraviolet B

URTI

Upper Respiratory Tract Infections

WHO

World Health Organisation

Data Availability

The data underlying this study are available on Figshare (DOI: 10.6084/m9.figshare.13726525).

Funding Statement

This study was supported by Murdoch Children's Research Institute in the form of funding awarded to SMG, Schlumberger foundation faculty for the future in the form of funding awarded to VO, Indonesia Endowment Fund for Education (LPDP) Ministry of Finance in the form of a grant awarded to VO (20130822080370), the David Bickart Clinician Research Fellowship from the University of Melbourne awarded to MD, Australia-Indonesia Centre (AIC) in the form of a grant awarded to MD and YS (01HSP1MELDancUGM003), and infrastructure funding from the Western Australian State Government, in partnership with the Australian Federal Government, through Bioplatforms Australia and the National Collaborative Research Infrastructure Strategy awarded to MWC. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

References

  • 1.Nair H, Simoes EA, Rudan I, Gessner BD, Azziz-Baumgartner E, Zhang JS, et al. Global and regional burden of hospital admissions for severe acute lower respiratory infections in young children in 2010: a systematic analysis. Lancet. 2013;381(9875):1380–90. 10.1016/S0140-6736(12)61901-1 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 2.Rudan I, O’Brien KL, Nair H, Liu L, Theodoratou E, Qazi S, et al. Epidemiology and etiology of childhood pneumonia in 2010: estimates of incidence, severe morbidity, mortality, underlying risk factors and causative pathogens for 192 countries. J Glob Health. 2013;3(1):010401. 10.7189/jogh.03.010401 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 3.Simoes EA, Cherian T, Chow J, Shahid-Salles SA, Laxminarayan R, John TJ. Acute respiratory infections in children. Disease Control Priorities in Developing Countries 2nd edition: The International Bank for Reconstruction and Development/The World Bank; 2006. p. 483–97. [Google Scholar]
  • 4.Liu L, Oza S, Hogan D, Perin J, Rudan I, Lawn JE, et al. Global, regional, and national causes of child mortality in 2000–13, with projections to inform post-2015 priorities: an updated systematic analysis. Lancet. 2015;385(9966):430–40. 10.1016/S0140-6736(14)61698-6 [DOI] [PubMed] [Google Scholar]
  • 5.McAllister DA, Liu L, Shi T, Chu Y, Reed C, Burrows J, et al. Global, regional, and national estimates of pneumonia morbidity and mortality in children younger than 5 years between 2000 and 2015: a systematic analysis. The Lancet Global Health. 2019;7(1):e47–e57. 10.1016/S2214-109X(18)30408-X [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 6.Collaborators GL. Estimates of the global, regional, and national morbidity, mortality, and aetiologies of lower respiratory tract infections in 195 countries: a systematic analysis for the Global Burden of Disease Study 2015. Lancet Infect Dis. 2017;17(11):1133–61. 10.1016/S1473-3099(17)30396-1 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 7.Rudan I, Boschi-Pinto C, Biloglav Z, Mullholland K, Campbell H. Epidemiology and etiology of childhood pneumonia. Bulletion if the World Health Organization. 2008;86:408–16. 10.2471/blt.07.048769 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 8.Lanata CF, Rudan I, Boschi-Pinto C, Tomaskovic L, Cherian T, Weber M, et al. Methodological and quality issues in epidemiological studies of acute lower respiratory infections in children in developing countries. Int J Epidemiol. 2004;33(6):1362–72. 10.1093/ije/dyh229 [DOI] [PubMed] [Google Scholar]
  • 9.Gessner BD, Sutanto A, Linehan M, Djelantik IG, Fletcher T, Gerudug IK, et al. Incidences of vaccine-preventable Haemophilus influenzae type b pneumonia and meningitis in Indonesian children: hamlet-randomised vaccine-probe trial. Lancet. 2005;365(9453):43–52. 10.1016/s0140-6736(04)17664-2 [DOI] [PubMed] [Google Scholar]
  • 10.Dunne EM, Murad C, Sudigdoadi S, Fadlyana E, Tarigan R, Indriyani SAK, et al. Carriage of Streptococcus pneumoniae, Haemophilus influenzae, Moraxella catarrhalis, and Staphylococcus aureus in Indonesian children: A cross-sectional study. PLoS One. 2018;13(4):e0195098. 10.1371/journal.pone.0195098 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 11.Gessner BD, Sutanto A, Steinhoff M, Soewignjo S, Widjaya A, Nelson C, et al. A population-based survey of Haemophilus influenzae type b nasopharyngeal carriage prevalence in Lombok Island, Indonesia. Pediatr Infect Dis J. 1998;17(9 Suppl):S179–82. 10.1097/00006454-199809001-00018 [DOI] [PubMed] [Google Scholar]
  • 12.Wahl B, O’Brien KL, Greenbaum A, Majumder A, Liu L, Chu Y, et al. Burden of Streptococcus pneumoniae and Haemophilus influenzae type b disease in children in the era of conjugate vaccines: global, regional, and national estimates for 2000–15. Lancet Glob Health. 2018;6(7):e744–e57. 10.1016/S2214-109X(18)30247-X [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 13.The Lancet Global H. The disgraceful neglect of childhood pneumonia. Lancet Glob Health. 2018;6(12):e1253. 10.1016/S2214-109X(18)30495-9 [DOI] [PubMed] [Google Scholar]
  • 14.Shibata T, Wilson JL, Watson LM, LeDuc A, Meng C, Ansariadi, et al. Childhood acute respiratory infections and household environment in an Eastern Indonesian urban setting. Int J Environ Res Public Health. 2014;11(12):12190–203. 10.3390/ijerph111212190 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 15.Lind T, Lonnerdal B, Stenlund H, Ismail D, Seswandhana R, Ekstrom EC, et al. A community-based randomized controlled trial of iron and zinc supplementation in Indonesian infants: interactions between iron and zinc. Am J Clin Nutr. 2003;77(4):883–90. 10.1093/ajcn/77.4.883 [DOI] [PubMed] [Google Scholar]
  • 16.Schlaudecker EP, Steinhoff MC, Moore SR. Interactions of diarrhea, pneumonia, and malnutrition in childhood: recent evidence from developing countries. Curr Opin Infect Dis. 2011;24(5):496–502. 10.1097/QCO.0b013e328349287d [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 17.Yakoob MY, Salam RA, Khan FR, Bhutta ZA. Vitamin D supplementation for preventing infections in children under five years of age. Cochrane Database of Systematic Reviews. 2016(11). 10.1002/14651858.CD008824.pub2 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 18.Haugen J, Basnet S, Hardang IM, Sharma A, Mathisen M, Shrestha P, et al. Vitamin D status is associated with treatment failure and duration of illness in Nepalese children with severe pneumonia. Pediatric research. 2017;82(6):986–93. 10.1038/pr.2017.71 [DOI] [PubMed] [Google Scholar]
  • 19.Mohamed WA, Al-Shehri MA. Cord blood 25-hydroxyvitamin D levels and the risk of acute lower respiratory tract infection in early childhood. J Trop Pediatr. 2013;59(1):29–35. 10.1093/tropej/fms042 [DOI] [PubMed] [Google Scholar]
  • 20.Haider N, Nagi AG, Khan KM. Frequency of nutritional rickets in children admitted with severe pneumonia. J Pak Med Assoc. 2010;60(9):729–32. [PubMed] [Google Scholar]
  • 21.Poh BK, Rojroongwasinkul N, Nguyen BK, Sandjaja, Ruzita AT, Yamborisut U, et al. 25-hydroxy-vitamin D demography and the risk of vitamin D insufficiency in the South East Asian Nutrition Surveys (SEANUTS). Asia Pac J Clin Nutr. 2016;25(3):538–48. 10.6133/apjcn.092015.02 [DOI] [PubMed] [Google Scholar]
  • 22.Mogire RM, Mutua A, Kimita W, Kamau A, Bejon P, Pettifor JM, et al. Prevalence of vitamin D deficiency in Africa: a systematic review and meta-analysis. Lancet Glob Health. 2020;8(1):e134–e42. 10.1016/S2214-109X(19)30457-7 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 23.Saraf R, Morton SM, Camargo CA Jr., Grant CC. Global summary of maternal and newborn vitamin D status—a systematic review. Matern Child Nutr. 2016;12(4):647–68. 10.1111/mcn.12210 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 24.Camargo CA Jr., Ingham T, Wickens K, Thadhani R, Silvers KM, Epton MJ, et al. Cord-blood 25-hydroxyvitamin D levels and risk of respiratory infection, wheezing, and asthma. Pediatrics. 2011;127(1):e180–7. 10.1542/peds.2010-0442 [DOI] [PubMed] [Google Scholar]
  • 25.Wang TT, Nestel FP, Bourdeau V, Nagai Y, Wang Q, Liao J, et al. Cutting edge: 1,25-dihydroxyvitamin D3 is a direct inducer of antimicrobial peptide gene expression. J Immunol. 2004;173(5):2909–12. 10.4049/jimmunol.173.5.2909 [DOI] [PubMed] [Google Scholar]
  • 26.Das RR, Singh M, Naik SS. Vitamin D as an adjunct to antibiotics for the treatment of acute childhood pneumonia. Cochrane Database of Systematic Reviews. 2018(7). 10.1002/14651858.CD011597.pub2 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 27.World Health Organization. Vitamin D supplementation and respiratory infections in children 2019 2019 [cited 2020 21 May]. Available from: https://www.who.int/elena/titles/vitamind_pneumonia_children/en/.
  • 28.Ariyawatkul K, Lersbuasin P. Prevalence of vitamin D deficiency in cord blood of newborns and the association with maternal vitamin D status. Eur J Pediatr. 2018;177(10):1541–5. 10.1007/s00431-018-3210-2 [DOI] [PubMed] [Google Scholar]
  • 29.Oktaria V, Graham SM, Triasih R, Soenarto Y, Bines JE, Ponsonby AL, et al. The prevalence and determinants of vitamin D deficiency in Indonesian infants at birth and six months of age. PLoS One. 2020;15(10):e0239603. 10.1371/journal.pone.0239603 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 30.Sandjaja, Budiman B, Harahap H, Ernawati F, Soekarti M, Widodo Y, et al. Food consumption and nutritional and biochemical status of 0.5–12 year old Indonesian children: the SEANUTS study. British Journal of Nutrition. 2013;110:S11–S20. 10.1017/S0007114513002109 [DOI] [PubMed] [Google Scholar]
  • 31.WHO. Revised WHO classification and treatment of childhood pneumonia at health facilities. Geneva: WHO Press; 2014. Available from: http://apps.who.int/iris/bitstream/10665/137319/1/9789241507813_eng.pdf. [Google Scholar]
  • 32.Clarke M, Tuckey R, Gorman S, Holt B, Hart P. Optimized 25-hydroxyvitamin D analysis using liquid–liquid extraction with 2D separation with LC/MS/MS detection, provides superior precision compared to conventional assays. Metabolomics. 2013;9(1):1031–40. [Google Scholar]
  • 33.Anders KL, Nguyen HL, Nguyen NM, Van Thuy NT, Hong Van NT, Hieu NT, et al. Epidemiology and virology of acute respiratory infections during the first year of life: a birth cohort study in Vietnam. Pediatr Infect Dis J. 2015;34(4):361–70. 10.1097/INF.0000000000000643 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 34.Sutanto A, Gessner B, Djlantik I, Steinhof M, Murphy H, Nelson C, et al. Acute Respiratory Illness Incidence and Death Among Children Under Two Years of Age on Lombok Island, Indonesia. Am J Trop MedHyg. 2002;66(2):175–9. 10.4269/ajtmh.2002.66.175 [DOI] [PubMed] [Google Scholar]
  • 35.le Roux DM, Myer L, Nicol MP, Zar HJ. Incidence and severity of childhood pneumonia in the first year of life in a South African birth cohort: the Drakenstein Child Health Study. Lancet Glob Health. 2015;3(2):e95–e103. 10.1016/S2214-109X(14)70360-2 [DOI] [PubMed] [Google Scholar]
  • 36.Jackson S, Mathews KH, Pulanic D, Falconer R, Rudan I, Campbell H, et al. Risk factors for severe acute lower respiratory infections in children: a systematic review and meta-analysis. Croat Med J. 2013;54(2):110–21. 10.3325/cmj.2013.54.110 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 37.Ahmed A, Ahmed T, Magalhaes RS, Long K, Alam M, Hossain M, et al. Association between serum vitamin D, retinol and zinc status, and acute respiratory infections in underweight and normal-weight children aged 6–24 months living in an urban slum in Bangladesh. Epidemiology & Infection. 2016;144(16):3494–506. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 38.Goodman D, Crocker ME, Pervaiz F, McCollum ED, Steenland K, Simkovich SM, et al. Challenges in the diagnosis of paediatric pneumonia in intervention field trials: recommendations from a pneumonia field trial working group. Lancet Respir Med. 2019;7(12):1068–83. 10.1016/S2213-2600(19)30249-8 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 39.Sudfeld CR, Manji KP, Smith ER, Aboud S, Kisenge R, Fawzi WW, et al. Vitamin D Deficiency Is Not Associated With Growth or the Incidence of Common Morbidities Among Tanzanian Infants. J Pediatr Gastroenterol Nutr. 2017;65(4):467–74. 10.1097/MPG.0000000000001658 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 40.Luczynska A, Logan C, Nieters A, Elgizouli M, Schottker B, Brenner H, et al. Cord blood 25(OH)D levels and the subsequent risk of lower respiratory tract infections in early childhood: the Ulm birth cohort. Eur J Epidemiol. 2014;29(8):585–94. 10.1007/s10654-014-9918-z [DOI] [PubMed] [Google Scholar]
  • 41.Martineau AR, Jolliffe DA, Hooper RL, Greenberg L, Aloia JF, Bergman P, et al. Vitamin D supplementation to prevent acute respiratory tract infections: systematic review and meta-analysis of individual participant data. BMJ. 2017;356:i6583. 10.1136/bmj.i6583 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 42.Manaseki-Holland S, Qader G, Isaq Masher M, Bruce J, Zulf Mughal M, Chandramohan D, et al. Effects of vitamin D supplementation to children diagnosed with pneumonia in Kabul: a randomised controlled trial. Trop Med Int Health. 2010;15(10):1148–55. 10.1111/j.1365-3156.2010.02578.x [DOI] [PubMed] [Google Scholar]
  • 43.Manaseki-Holland S, Maroof Z, Bruce J, Mughal MZ, Masher MI, Bhutta ZA, et al. Effect on the incidence of pneumonia of vitamin D supplementation by quarterly bolus dose to infants in Kabul: a randomised controlled superiority trial. Lancet. 2012;379(9824):1419–27. 10.1016/S0140-6736(11)61650-4 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 44.Bolland MJ, Avenell A. Do vitamin D supplements help prevent respiratory tract infections? BMJ. 2017;356:j456. 10.1136/bmj.j456 [DOI] [PubMed] [Google Scholar]
  • 45.Bhutta ZA. Vitamin D reduces respiratory tract infections frequency. J Pediatr. 2017;186:209–12. 10.1016/j.jpeds.2017.04.021 [DOI] [PubMed] [Google Scholar]
  • 46.Zisi D, Challa A, Makis A. The association between vitamin D status and infectious diseases of the respiratory system in infancy and childhood. Hormones (Athens). 2019;18(4):353–63. 10.1007/s42000-019-00155-z [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 47.Kimball S, Vieth R, Dosch HM, Bar-Or A, Cheung R, Gagne D, et al. Cholecalciferol plus calcium suppresses abnormal PBMC reactivity in patients with multiple sclerosis. J Clin Endocrinol Metab. 2011;96(9):2826–34. 10.1210/jc.2011-0325 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 48.Felton SJ, Cooke MS, Kift R, Berry JL, Webb AR, Lam PM, et al. Concurrent beneficial (vitamin D production) and hazardous (cutaneous DNA damage) impact of repeated low-level summer sunlight exposures. Br J Dermatol. 2016;175(6):1320–8. 10.1111/bjd.14863 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 49.Telcian AG, Zdrenghea MT, Edwards MR, Laza-Stanca V, Mallia P, Johnston SL, et al. Vitamin D increases the antiviral activity of bronchial epithelial cells in vitro. Antiviral Res. 2017;137:93–101. 10.1016/j.antiviral.2016.11.004 [DOI] [PubMed] [Google Scholar]
  • 50.Gupta P, Dewan P, Shah D, Sharma N, Bedi N, Kaur IR, et al. Vitamin D Supplementation for Treatment and Prevention of Pneumonia in Under-five Children: A Randomized Double-blind Placebo Controlled Trial. Indian Pediatr. 2016;53(11):967–76. 10.1007/s13312-016-0970-5 [DOI] [PubMed] [Google Scholar]

Decision Letter 0

Pal Bela Szecsi

30 Dec 2020

PONE-D-20-33592

The incidence of acute respiratory infection in Indonesian infants and association with vitamin D deficiency

PLOS ONE

Dear Dr. Oktaria,

Thank you for submitting your manuscript to PLOS ONE. After careful consideration, we feel that it has merit but does not fully meet PLOS ONE’s publication criteria as it currently stands. Therefore, we invite you to submit a revised version of the manuscript that addresses the points raised during the review process.

I must congratulate the authors for a well-performed study that enlighten the risk of vitamin D deficiency in childhood.

In addition to the issues raised by the reviewers, please provide a little more details about the performance of the vitamin D assay (CV, internal standard, QC data). I appreciate that they have use MS method rather than immunological methods, but is both D2 and D3 measured. Also, please consider the definition of deficiency 25/50/75 nmol/L, is that cast in bronze? Considering that you have measured with a relatively reliable method a quantitative test rather than categorical (deficiency or not) would have been preferable.

You have considered maternal sun exposition as D3 source, I assume that season is less likely to influence this as Indonesia is close to equator, but is social factors involved (clothing?). Also, please provide a note on maritime diet.

Please submit your revised manuscript by Feb 13 2021 11:59PM. If you will need more time than this to complete your revisions, please reply to this message or contact the journal office at plosone@plos.org. When you're ready to submit your revision, log on to https://www.editorialmanager.com/pone/ and select the 'Submissions Needing Revision' folder to locate your manuscript file.

Please include the following items when submitting your revised manuscript:

  • A rebuttal letter that responds to each point raised by the academic editor and reviewer(s). You should upload this letter as a separate file labeled 'Response to Reviewers'.

  • A marked-up copy of your manuscript that highlights changes made to the original version. You should upload this as a separate file labeled 'Revised Manuscript with Track Changes'.

  • An unmarked version of your revised paper without tracked changes. You should upload this as a separate file labeled 'Manuscript'.

If you would like to make changes to your financial disclosure, please include your updated statement in your cover letter. Guidelines for resubmitting your figure files are available below the reviewer comments at the end of this letter.

If applicable, we recommend that you deposit your laboratory protocols in protocols.io to enhance the reproducibility of your results. Protocols.io assigns your protocol its own identifier (DOI) so that it can be cited independently in the future. For instructions see: http://journals.plos.org/plosone/s/submission-guidelines#loc-laboratory-protocols

We look forward to receiving your revised manuscript.

Kind regards,

Pal Bela Szecsi, M.D. D.M.Sci.

Academic Editor

PLOS ONE

Journal Requirements:

When submitting your revision, we need you to address these additional requirements.

1. Please ensure that your manuscript meets PLOS ONE's style requirements, including those for file naming. The PLOS ONE style templates can be found at

https://journals.plos.org/plosone/s/file?id=wjVg/PLOSOne_formatting_sample_main_body.pdf and

https://journals.plos.org/plosone/s/file?id=ba62/PLOSOne_formatting_sample_title_authors_affiliations.pdf

2. Please provide additional details regarding participant consent. In the ethics statement in the Methods and online submission information, please ensure that you have specified whether consent was informed.

3. Please include additional information regarding the structured questionnaires and telephone interview guides used in the study and ensure that you have provided sufficient details that others could replicate the analyses.

For instance, if you developed the questionnaires/guides as part of this study and they are not under a copyright more restrictive than CC-BY, please include a copy, in both the original language and English, as Supporting Information.

4. Please state the date range of patient recruitment (month and year).

5. Please list the nine Primary Healthcare Centres and five private practice clinics where patients were recruited from.

[Note: HTML markup is below. Please do not edit.]

Reviewers' comments:

Reviewer's Responses to Questions

Comments to the Author

1. Is the manuscript technically sound, and do the data support the conclusions?

The manuscript must describe a technically sound piece of scientific research with data that supports the conclusions. Experiments must have been conducted rigorously, with appropriate controls, replication, and sample sizes. The conclusions must be drawn appropriately based on the data presented.

Reviewer #1: Partly

Reviewer #2: Yes

**********

2. Has the statistical analysis been performed appropriately and rigorously?

Reviewer #1: Yes

Reviewer #2: Yes

**********

3. Have the authors made all data underlying the findings in their manuscript fully available?

The PLOS Data policy requires authors to make all data underlying the findings described in their manuscript fully available without restriction, with rare exception (please refer to the Data Availability Statement in the manuscript PDF file). The data should be provided as part of the manuscript or its supporting information, or deposited to a public repository. For example, in addition to summary statistics, the data points behind means, medians and variance measures should be available. If there are restrictions on publicly sharing data—e.g. participant privacy or use of data from a third party—those must be specified.

Reviewer #1: Yes

Reviewer #2: No

**********

4. Is the manuscript presented in an intelligible fashion and written in standard English?

PLOS ONE does not copyedit accepted manuscripts, so the language in submitted articles must be clear, correct, and unambiguous. Any typographical or grammatical errors should be corrected at revision, so please note any specific errors here.

Reviewer #1: Yes

Reviewer #2: Yes

**********

5. Review Comments to the Author

Please use the space provided to explain your answers to the questions above. You may also include additional comments for the author, including concerns about dual publication, research ethics, or publication ethics. (Please upload your review as an attachment if it exceeds 20,000 characters)

Reviewer #1: Oktaria et al. tried to investigate the vitamin-D levels of the ARI affected infants and the possible correlation of this vitamin with the incidence of ARI. Eventually they concluded that Vitamin D deficiency was associated with the incidence of ARI but not of pneumonia in the first year of life but adequate maternal sun exposure during pregnancy was associated with a trend to less frequent ARI and pneumonia in Indonesian infants.

My observations-

1. Here the authors mentioned that similar prospective cohort community-based cohort studies that measure actual pneumonia incidence are limited. However, if they can compare or discuss results from any other Indonesian or South Asian studies about ARI in infants especially with regards to immunization/breastfeeding practices/socioeconomic status, it would make the research paper even better and add more credibility to the results.

2. Despite the great efforts of the authors, the data obtained in this study lacks innovation, it is recommended that the paper be submitted to the local journals.

Reviewer #2: Uploaded as an attachment.

Please note data and scripts are not available to the reviewers.

##########################################################

##########################################################

**********

6. PLOS authors have the option to publish the peer review history of their article (what does this mean?). If published, this will include your full peer review and any attached files.

If you choose “no”, your identity will remain anonymous but your review may still be made public.

Do you want your identity to be public for this peer review? For information about this choice, including consent withdrawal, please see our Privacy Policy.

Reviewer #1: Yes: Md. Rabiul Islam

Reviewer #2: Yes: Antonio J Berlanga-Taylor

[NOTE: If reviewer comments were submitted as an attachment file, they will be attached to this email and accessible via the submission site. Please log into your account, locate the manuscript record, and check for the action link "View Attachments". If this link does not appear, there are no attachment files.]

While revising your submission, please upload your figure files to the Preflight Analysis and Conversion Engine (PACE) digital diagnostic tool, https://pacev2.apexcovantage.com/. PACE helps ensure that figures meet PLOS requirements. To use PACE, you must first register as a user. Registration is free. Then, login and navigate to the UPLOAD tab, where you will find detailed instructions on how to use the tool. If you encounter any issues or have any questions when using PACE, please email PLOS at figures@plos.org. Please note that Supporting Information files do not need this step.

Attachment

Submitted filename: Review Comments.docx

Attachment

Submitted filename: review_Oktaria_et_al_PONE-D-20-33592_24_Dec_2020.docx

PLoS One. 2021 Mar 23;16(3):e0248722. doi: 10.1371/journal.pone.0248722.r002

Author response to Decision Letter 0


8 Feb 2021

The incidence of acute respiratory infection in Indonesian infants and association with vitamin D deficiency

Submission ID: PONE-D-20-33592

Response to reviewers:

Editor

I must congratulate the authors for a well-performed study that enlighten the risk of vitamin D deficiency in childhood. In addition to the issues raised by the reviewers, please provide a little more detail about the performance of the vitamin D assay (CV, internal standard, QC data). I appreciate that they have use MS method rather than immunological methods but is both D2 and D3 measured. Also, please consider the definition of deficiency 25/50/75 nmol/L, is that cast in bronze? Considering that you have measured with a relatively reliable method a quantitative test rather than categorical (deficiency or not) would have been preferable.

Author response:

Many thanks for your positive comment. We have added some information on the Coefficient of Variability (CV), internal standard and Quality control data as stated in the paper – Methods, Page 9 -10, line 197 - 209. The assay gives excellent separation of epi-25(OH)D3, and 25(OH)D2 from 25(OH)D3, has excellent precision with an intra-assay CV of 0.5 % at 74 nmol/L for 25(OH)D3.

In our recently published paper, we categorised vitamin D deficiency using different cut-offs [Oktaria V, et al. (2020) The prevalence and determinants of vitamin D deficiency in Indonesian infants at birth and six months of age. PLoS ONE 15(10): e0239603.] We have run analysis in the current manuscript using different cut-offs of <25 and <75 nmol/L but this did not substantially change the results in comparison with a cut-off of <50 nmol/L. We therefore use < 50 nmol/L for the definition of deficiency as it is the most commonly reported in measuring the association between respiratory infections and vitamin D deficiency.

Change in the manuscript: Page 9 -10, line 197 - 209

“Sera from cord blood and venous blood were assayed at Metabolomics Australia, Centre for Microscopy, Characterisation, and Analysis, University of Western Australia. The total serum 25-hydroxyvitamin D concentrations were measured using liquid chromatography-tandem mass spectrometry, the current gold standard for vitamin D measurement, which has shown excellent agreement with Center for Disease Control and Prevention’s 25-hydroxyvitamin D inaugural Vitamin D standardisation program (r2 =0.99) (31). The analytical sensitivity (or limit of detection) and the functional sensitivity (or limit of quantitation) of the assay for 25-hydroxyvitamin D3 is 0.5 nM and 2 nmol/L respectively.

Commercial quality controls are assayed at the beginning and end of each batch, with intra-assay Coefficient of variability’s (CV’s) for all three metabolites <5%, with inter-assay CV’s being <10%. Internal standard peak areas are monitored for each batch and are <10% within each run. We defined vitamin D deficiency as a serum 25-hydroxyvitamin D3 level of <50 nmol/L.”

You have considered maternal sun exposition as D3 source, I assume that season is less likely to influence this as Indonesia is close to equator, but is social factors involved (clothing?). Also, please provide a note on maritime diet.

Author response:

As you suggest, Indonesia has limited seasonal fluctuation of sun exposure. During our study period 2015 - 2017, the median of sun exposure was 266 (IQR 242 – 290) mW/m2/day. We have included discussion about maternal clothing and infant diet in a separate publication where we reported that “only 5% of our study infants had egg yolk in the first six months, mainly those who were living in the rural area, and even less had had fish or red meats.”. [Oktaria V, et al. (2020) The prevalence and determinants of vitamin D deficiency in Indonesian infants at birth and six months of age. PLoS ONE 15(10): e0239603.] We collected information on maritime diet (seafood intake) in infants but unfortunately not in mothers.

We also reported in the publication that time spent outdoor during pregnancy was associated with cord blood vitamin D concentration. Clothing (represented by skin sun exposure score) was associated with vitamin D concentration in infant but not in mother. However, other study from Indonesia reported a significant association between vitamin D status and maternal clothing [Judistiani RTD, et al. Optimizing ultra- violet B radiation exposure to prevent vitamin D deficiency among pregnant women in the tropical zone: report from cohort study on vitamin D status and its impact during pregnancy in Indonesia. BMC Pregnancy Childbirth. 2019; 19(1):209. https://doi.org/10.1186/s12884-019-2306-7 PMID: 31226954].

Change made in the manuscript: None

Additional requirement from the journals

1. Please ensure that your manuscript meets PLOS ONE's style requirements, including those for file naming. The PLOS ONE style templates can be found at

Author response:

We have followed the recommended guideline.

2. Please provide additional details regarding participant consent. In the ethics statement in the Methods and online submission information, please ensure that you have specified whether consent was informed.

Author response:

We have now amended the sentences in the Methods, Page 7-8, Line 156 – 159

Change made in the manuscript:

“Informed consent was obtained prior to delivery and included the intention to actively follow infants for 12 months, and to collect cord blood at delivery and a venous blood sample at six months of age. Written informed consent was reaffirmed after delivery of a live birth.”

3. Please include additional information regarding the structured questionnaires and telephone interview guides used in the study and ensure that you have provided sufficient details that others could replicate the analyses.

For instance, if you developed the questionnaires/guides as part of this study and they are not under a copyright more restrictive than CC-BY, please include a copy, in both the original language and English, as Supporting Information.

Author response

Yes, we have included the questionnaire as supporting information (S1 Files)

4. Please state the date range of patient recruitment (month and year).

Author response:

Dates now added in Abstract Page 3, Line 44-45 and Result section Page 11, Line 239 -240

Change made in the manuscript:

Between 23 December 2015 and 31 December 2017, we recruited 422 participants with 95% (400/422) of infants retained for the full twelve months of follow-up.

5. Please list the nine Primary Healthcare Centres and five private practice clinics where patients were recruited from.

Author response :

We have now listed the clinics in Page 7, line 143 – 146

Change made in the manuscript:

A prospective birth cohort study was conducted in nine Primary Healthcare Centres (Jetis, Tegalrejo, Gedongtengen, Gondokusuman 2, Mantrijeron, Gondomanan, Wates, Sentolo, Pengasih 1) and five private practice clinics (Sri Suharti, Suwarti, Sulalita, Sri Suyantiningsih, and Sri Esthini) located in two districts in Yogyakarta province, Indonesia.

Reviewer 1

1. Here the authors mentioned that similar prospective cohort community-based cohort studies that measure actual pneumonia incidence are limited. However, if they can compare or discuss results from any other Indonesian or South Asian studies about ARI in infants especially with regards to immunization/breastfeeding practices/socioeconomic status, it would make the research paper even better and add more credibility to the results.

Author response:

Thank you for highlighting this point. Prospective studies of ARI incidence in infants in Indonesia or the region are limited. The additional challenge for comparison is that other studies utilize variable definitions of ARI, URTI and LRTI as well as methods of ARI case ascertainment. Standardization of ARI criteria are important because application of different definitions to the same cohort could substantially change the reported burden.

Most “current” data are from epidemiological modelling. For example, Rudan I et al. conducted periodical epidemiological modeling for pneumonia burden in 2004, 2008 and 2013 and showed little variation in the included studies from one period to the other. A recognised limitation for epidemiological analysis was the “slow growth” of prospective studies on pneumonia incidence. This meant that the statistical predictive model was partly influenced by studies that were published prior to 2000, and yet the incidence may have been overestimated because the epidemiology is likely changing.

We have now cited important publications from the region that link known risk factors for ARI such as exclusive breastfeeding, poverty and ARI in Introduction section, Page 6, Line 118 - 121

Change made in the manuscript:

ARI risk factors in Indonesia are similar to the global population. These include poverty, indoor pollution, suboptimum exclusive breastfeeding and poor nutritional status.[5, 14] Nutritional deficiency, including both macro and micronutrient deficiencies, is common in Indonesian children [15, 16].

2. Despite the great efforts of the authors, the data obtained in this study lacks innovation, it is recommended that the paper be submitted to the local journals.

Author response:

Thank you very much for the suggestions. We believe that our study results could provide some valuable information for other countries that shared similar geographic, cultural and religious backgrounds with Indonesia. The wide range of PLOS ONE readers would enhance the dissemination of our study results.

Change made in the manuscript: None

Reviewer 2

Abstract

1. Lines 62-63: Conclusion: Minimising vitamin D deficiency at birth such as by supplementation or safe sun exposure has the potential to reduce ARI incidence in infants in this setting.” >Supplementation of mothers during pregnancy?

Author response:

We have amended the sentences

Change made in the manuscript: Page 4, line 62 – 64

ARI, pneumonia, and vitamin D deficiency at birth were common in Indonesian infants. Minimising vitamin D deficiency at birth such as by supplementation of mothers or safe sun exposure during pregnancy has the potential to reduce ARI incidence in infants in this setting.

Introduction

2. The introduction is informative, presents some background knowledge on the subject and literature. However, I would suggest providing some more specific information on the Indonesian population e.g.:

a. What is the prevalence of ARI in Indonesia, how many infants diagnosed each year, mortality rate, etc.

Author response:

We have added such information - Page 5, Line 96 - 100

Change made in the manuscript:

In the same year, the total number of estimated pneumonia episodes in Indonesian children aged younger than five years old were 3,196,000 episodes (2,447,000 to 3,666,000 episodes), with an incidence rate of ~ 300 cases per 1000 population.(1, 3) The total number of estimated deaths reported in that year was 15,250 deaths (9,900 to 20,124 deaths) (2, 5-7).

b. What are some known risk factors of ARIs and how does this relate to the Indonesian population?

Author response:

We have added more information - Page 6, Line 118 - 121

Change made in the manuscript:

ARI risk factors in Indonesia are similar to the global population. These include poverty, indoor pollution, suboptimum exclusive breastfeeding and poor nutritional status.[5, 14] Nutritional deficiency, including both macro and micronutrient deficiencies, is common in Indonesian children [15, 16].

c. Are ARIs the leading cause of death in Indonesian children? What about different age groups?

Author response:

We have added further information - Page 5, Line 96 - 100

Change made in the manuscript:

In the same year, the total number of estimated pneumonia episodes in Indonesian children aged younger than five years old were 3,196,000 episodes (2,447,000 to 3,666,000 episodes), with an incidence rate of ~ 300 cases per 1000 population.(1, 3) The total number of estimated deaths reported in that year was 15,250 deaths (9,900 to 20,124 deaths) (2, 5-7).

d. Also, some additional background information is required regarding pneumonia in children.

Author response:

We have added some information as described above in the response to query 2 a-c

e. What about prevalence of vitamin D deficiency in Indonesian children?

Author response:

We have added information: Page 7, line 134 – 135

Change made in the manuscript:

The prevalence of vitamin D deficiency in Indonesia children aged 2-5 years old was 44% and newborns have been reported at high risk of vitamin D deficiency (28, 29).

3. Line 109-111: discussion of limited evidence currently reads a bit confusing, would recommend some re-wording.

Author response:

We have amended the sentences - Page 6, line 127 – 130.

Change made in the manuscript:

There is biological plausibility for this association given the immunomodulatory effects of vitamin D deficiency (24). However, a limited number of studies on vitamin D supplementation in children with ARI have been published to date and evidence of a convincing association with prevention or treatment of outcomes is still lacking. (16, 25).

4. Lines 85-91 >After line 86 I would suggest having a sentence to introduce the reader that ARI can affect either upper respiratory system or lower respiratory system and then go into details of each URTI, LRTI, and pneumonia more specifically.

Author response:

We have amended the sentences - Page 5, line 87 – 91

Change made in the manuscript:

Acute respiratory infection (ARI) is the leading cause of disease and death in young children (<5 years) globally (1, 2). ARI incorporates a wide range of respiratory illnesses, from mild to life-threatening, that are classified based on location of infection in relation to the vocal cords into: upper respiratory tract infection (URTI) such as rhinitis, nasopharyngitis, tonsillitis, or epiglottitis; and lower respiratory tract infection (LRTI) such as pneumonia, bronchiolitis or croup (3). Upper respiratory tract infection (URTI) is a very common outpatient presentation associated with low mortality but significant health systems costs (1, 4)

5. Line 95 >Please provide more details regarding the Haemophilus influenzae type b vaccine in the introduction e.g. When was it implemented? Does it prevent pneumonia?

Author response:

We have amended the sentences - Page 5-6, Line 107 - 114

Change made in the manuscript:

The major recognised bacterial pathogens causing pneumonia, influencing global efforts to prevent pneumonia-related deaths through case management and vaccines have been Streptococcus pneumoniae and Haemophilus influenzae type b (Hib) (2). Since the Hib vaccine was included in the routine immunisation schedule in 2013, the prevalence of Hib carriage has been shown to decline to 0% compared to 5% as reported in 1998 (10, 11). With socioeconomic development and the introduction of bacterial conjugate vaccines, the epidemiology is changing with a relatively larger proportion of ARI due to viruses and a lower mortality attributed to ARI (12).

6. Page 5 lines 106-108 “Subclinical vitamin D deficiency (serum vitamin D <50 nmol/L) is far more common and has…” And Line 180: We defined vitamin D deficiency as a serum 25-hydroxyvitamin D level of <50nmol/L.

a. It would be good to provide a reference for these statements.

b. Add “far more common in infants” if this is this what the sentence implies.

Author response:

We have amended the sentences and added reference for the statement - Page 6, line 124 - 127

Change made in the manuscript:

Subclinical vitamin D deficiency (serum vitamin D <50 nmol/L) is far more common than clinical rickets in young children (20-22) and has also been associated with ARI, including increased risk of URTI, LRTI, and LRTI hospitalisation (17, 18, 23).

7. Page 6 lines 108-111 “However, evidence of a causal relationship is inconclusive and limited studies of vitamin D supplementation have not yet demonstrated benefit for prevention or treatment outcomes [9, 15]”

a. I assume the abovementioned limited studies are in children, or do they include adults as well?

b. Could rephrase to: A limited number of studies on vitamin D supplementation in children with ARI have been published to date and evidence of a convincing association with prevention or treatment of outcomes is still lacking.

Author response:

Yes, it is correct that we highlighted the limited evidence in children. We have rephrased as suggested. Page 6, Line 127 - 130

Change made in the manuscript:

There is biological plausibility for this association given the immunomodulatory effects of vitamin D deficiency (24). However, a limited number of studies on vitamin D supplementation in children with ARI have been published to date and evidence of a convincing association with prevention or treatment of outcomes is still lacking. (16, 25).

8. Line 129 Study procedures: Any exclusion criteria that should be mentioned? Both parents were interviewed or only mother?

Author response:

We primarily interviewed mother

We have amended the sentences and added the exclusion criteria - Page 7, Line 154 - 156

Change made in the manuscript:

Inclusion criteria included expected delivery in one of the study sites without intention to leave the area within 12 months. Parents who did not provide written informed consent for their child’s participation or who did not have phone access were not included.

9. Lines 146-147 “ if the participants reported cough for more than three days to obtain the respiratory rate” >Do the participants imply the infants? And whenever the word participants is used I would suggest to use infants for consistency.

Author response:

Yes, participant imply infants. We have amended as suggested

Change made in the manuscript:

Replacement of participants into infants throughout the draft have been done as appropriate

10. Line 150 according to WHO guidelines > Reference?

Author response:

We have added a reference to the related sentence.

Methods

11. Line 144: It would be good to have a description of what constituted “respiratory symptoms”. It is a bit unclear if a classification of “ARI non-pneumonia episode” required a home visit to be considered for the study (e.g. cough over 3 days?) and how these episodes were categorized.

Author response:

We have clarified the definition for ARI non pneumonia. Page 9. Line 185 - 187

The initial symptom of ARI pneumonia and non-pneumonia could be similar. We performed home visit and maintained regular contacts during symptomatic period to monitor if the symptoms worsening. Categorisation by WHO criteria for pneumonia was used and decision for the final diagnosis were discussed by the study doctor team led by paediatric respiratory experts.

Change made in the manuscript:

ARI non-pneumonia episode was defined for respiratory symptoms (including runny nose, fever, sore throat and/or cough) without fast breathing or chest indrawing.

Statistical analysis

12. Which confounders were considered for the Cox Regression, please provide more details.

Author response:

We have listed the adjusted confounders for each evaluated association below Table 5. Confounding was determined: if the difference between the Odd Ratio (OR) or Hazard Ratio (HR) in the univariate and multivariate models changed by more than 10% or based on a priori knowledge.

13. I can see that certain sensitivity analyses were conducted e.g. using a lower cut-off for vitamin D (level of <25) but these are not measured in methods. It would be good to mention these in the statistical analysis.

Author response:

We have added sensitivity analysis in the method section - Page 10, Line 228 - 230

Change made in the manuscript:

A sensitivity analysis using a lower cut off vitamin D level of <25 nmol/L (severe vitamin D deficiency) and a higher cut off vitamin D level of < 75 nmol/L was performed.

14. Was the proportional hazards assumption for Cox proportional hazards models tested?

Author response:

We have now added the Kaplan-Meier plots in the draft (Fig 2) and the graphs show parallel curves that crossing at some points. The hazard rates were not different between those with and without vitamin D deficiency at birth and at six months of age.

15. I don’t see any apparent risk of immortal person time according to classification of exposures and outcomes.

Author response:

We do not quite understand this query. Would the reviewer please kindly explain in more detail?

16. Line 171-172: It is possible that seasonality impacts maternal sun exposure, unclear if this is accounted for in the calculation of cumulative composite estimate UVR (Wierzejska, R., Jarosz, M., Sawicki, W., Bachanek, M. and Siuba-Strzelińska, M., 2017. Vitamin D concentration in maternal and umbilical cord blood by season. International journal of environmental research and public health, 14(10), p.1121.)

Author response:

Indonesia has year round sun exposure with limited seasonal fluctuation. During our study period 2015 - 2017, the median of sun exposure was 266 (IQR 242 – 290) mW/m2/day.

Maternal sun exposures are greatly influenced by clothing preference that was strongly affected by religious beliefs (Muslim population). Muslim female wear covering clothes (hijab) regardless the season/whether condition. Our recent published work reported that majority (90%) of our participating infants were vitamin D deficiency at birth with longer time outdoors during pregnancy and maternal multivitamin and maternal multivitamin intake containing vitamin D during pregnancy were protective against vitamin D deficiency at birth [Oktaria V, et al. (2020) The prevalence and determinants of vitamin D deficiency in Indonesian infants at birth and six months of age. PLoS ONE 15(10): e0239603.]

17. Data are not available to reviewers. Please upload these and deposit somewhere accessible.

Author response:

We have now deposited our data in Figshare, DOI: 10.6084/m9.figshare.13726525

18. Analyses scripts are not available either. Please upload these as well and deposit somewhere accessible.

Author response:

We have now deposited our do file analysis in Figshare, DOI: 10.6084/m9.figshare.13726525

Results

19. “Between December 2015 and December 2017, we recruited 422 participants with 95% 210 (400/422) of infants retained for the full twelve months of follow-up.”

a. Participant is mothers or infants?

b. Any important information for those lost to follow up?

Author response:

Participants are infants and we have amended the wording throughout the draft

We have listed all information in Figure 1. The time period of observation for each infant was determined as the period in days from the date of birth until the date of the last contact made (final follow-up, prior to lost to follow-up or date of death). All ARI outcomes reported prior to loss of contact were analyzed.

20. Please show plots as well as tables.

Author response:

We have reported plots on the prevalence of infant vitamin D deficiency and correlation between cord blood and six-month blood vitamin D level in a separate publication [Oktaria V, et al. (2020) The prevalence and determinants of vitamin D deficiency in Indonesian infants at birth and six months of age. PLoS ONE 15(10): e0239603.].

We have now added the Kaplan Meier plots for association between vitamin D status and pneumonia in this draft (Fig 2).

Change made in the manuscript:

Figure 2 Time to develop first episode of pneumonia by vitamin D status at birth and 6 months of age

21. Lines 224-225 The demographics characteristics of those with vitamin D samples at birth and six months of 225 age were representative of the entire cohort (Table 1).

a. Specify “those”, infants?

b. Change participants to infants in Table 1

Author response:

Participants are infants and we have amended the wording throughout the draft. We have edited the statement on Page 11, Line 254 - 255

Change made in the manuscript:

The demographics characteristics of infants with vitamin D samples at birth and six months of age were representative of the entire cohort (Table 1).

Discussion

22. Line 349-350: A major potential confounder exists in the assessment of maternal sun exposure – since this is likely to be higher in more rural areas and infections may be more prevalent in urban ones. Was there any measure available for urbanicity? Household crowding was considered but it is not reflective of wider environment.

Author response:

The inclusion of urbanicity did not materially change the association between maternal sun exposure and pneumonia and did not change the strength of the association in the multivariate models.

Change made in the manuscript: None

23. Line 361: Vitamin D supplementation is discussed, was there any data collection on maternal use of supplements?

Author response:

Maternal vitamin D supplementation in pregnant women was not standard recommendation in our setting. A minority (7%) of mothers reported taking a multivitamin supplement that contained vitamin D during pregnancy with 50% reporting a daily vitamin D intake below 400 IU, the minimum recommended daily dose in pregnancy. Due to very low proportion of infants whose mothers had taken multivitamin supplement that contained vitamin D, we were unable to do further analysis.

24. It seems a bit odd to me that deficiency according to cord blood would be so high, is this normal? I couldn’t find similar figures through a quick literature search.

Author response:

A similar study from Thailand demonstrated similar high prevalence of vitamin D deficiency in newborn (89.3%) [Ariyawatkul, K. and P. Lersbuasin (2018). "Prevalence of vitamin D deficiency in cord blood of newborns and the association with maternal vitamin D status." Eur J Pediatr 177(10): 1541-1545].

It is perhaps not surprising as a high prevalence of vitamin D deficiency was also reported in Indonesian mothers in pregnancy which half of them wore veils and covering clothes (80.4%). [Judistiani RTD, et al. Optimizing ultraviolet B radiation exposure to prevent vitamin D deficiency among pregnant women in the tropical zone: report from cohort study on vitamin D status and its impact during pregnancy in Indonesia. BMC Pregnancy Childbirth. 2019; 19(1):209. https://doi.org/10.1186/s12884-019-2306-7 PMID: 31226954].

Attachment

Submitted filename: Response to the reviewers.docx

Decision Letter 1

Pal Bela Szecsi

4 Mar 2021

The incidence of acute respiratory infection in Indonesian infants and association with vitamin D deficiency

PONE-D-20-33592R1

Dear Dr. Oktaria,

We’re pleased to inform you that your manuscript has been judged scientifically suitable for publication and will be formally accepted for publication once it meets all outstanding technical requirements.

Within one week, you’ll receive an e-mail detailing the required amendments. When these have been addressed, you’ll receive a formal acceptance letter and your manuscript will be scheduled for publication.

An invoice for payment will follow shortly after the formal acceptance. To ensure an efficient process, please log into Editorial Manager at http://www.editorialmanager.com/pone/, click the 'Update My Information' link at the top of the page, and double check that your user information is up-to-date. If you have any billing related questions, please contact our Author Billing department directly at authorbilling@plos.org.

If your institution or institutions have a press office, please notify them about your upcoming paper to help maximize its impact. If they’ll be preparing press materials, please inform our press team as soon as possible -- no later than 48 hours after receiving the formal acceptance. Your manuscript will remain under strict press embargo until 2 pm Eastern Time on the date of publication. For more information, please contact onepress@plos.org.

Kind regards,

Pal Bela Szecsi, M.D. D.M.Sci.

Academic Editor

PLOS ONE

Additional Editor Comments (optional):

Reviewers' comments:

Reviewer's Responses to Questions

Comments to the Author

1. If the authors have adequately addressed your comments raised in a previous round of review and you feel that this manuscript is now acceptable for publication, you may indicate that here to bypass the “Comments to the Author” section, enter your conflict of interest statement in the “Confidential to Editor” section, and submit your "Accept" recommendation.

Reviewer #1: All comments have been addressed

Reviewer #2: All comments have been addressed

**********

2. Is the manuscript technically sound, and do the data support the conclusions?

The manuscript must describe a technically sound piece of scientific research with data that supports the conclusions. Experiments must have been conducted rigorously, with appropriate controls, replication, and sample sizes. The conclusions must be drawn appropriately based on the data presented.

Reviewer #1: Partly

Reviewer #2: Yes

**********

3. Has the statistical analysis been performed appropriately and rigorously?

Reviewer #1: Yes

Reviewer #2: Yes

**********

4. Have the authors made all data underlying the findings in their manuscript fully available?

The PLOS Data policy requires authors to make all data underlying the findings described in their manuscript fully available without restriction, with rare exception (please refer to the Data Availability Statement in the manuscript PDF file). The data should be provided as part of the manuscript or its supporting information, or deposited to a public repository. For example, in addition to summary statistics, the data points behind means, medians and variance measures should be available. If there are restrictions on publicly sharing data—e.g. participant privacy or use of data from a third party—those must be specified.

Reviewer #1: Yes

Reviewer #2: Yes

**********

5. Is the manuscript presented in an intelligible fashion and written in standard English?

PLOS ONE does not copyedit accepted manuscripts, so the language in submitted articles must be clear, correct, and unambiguous. Any typographical or grammatical errors should be corrected at revision, so please note any specific errors here.

Reviewer #1: Yes

Reviewer #2: Yes

**********

6. Review Comments to the Author

Please use the space provided to explain your answers to the questions above. You may also include additional comments for the author, including concerns about dual publication, research ethics, or publication ethics. (Please upload your review as an attachment if it exceeds 20,000 characters)

Reviewer #1: Thanks to the authors for addressing my observations. The other reviewers noted several issues along with editorial comments and many changes have been made. Indeed, the paper is improved and I recommend publication.

Reviewer #2: No further comments from our side. If external replication confirms results it would certainly have important public health implications with potential for changing national policy. I hope authors can follow-up in a separate study and/or collaborate with a group in a different city/province. Many thanks for the detailed response and congratulations on an interesting paper.

**********

7. PLOS authors have the option to publish the peer review history of their article (what does this mean?). If published, this will include your full peer review and any attached files.

If you choose “no”, your identity will remain anonymous but your review may still be made public.

Do you want your identity to be public for this peer review? For information about this choice, including consent withdrawal, please see our Privacy Policy.

Reviewer #1: Yes: Md. Rabiul Islam, Assistant Professor, Department of Pharmacy, University of Asia Pacific, Dhaka, Bangladesh

Reviewer #2: Yes: Antonio Berlanga

Acceptance letter

Pal Bela Szecsi

15 Mar 2021

PONE-D-20-33592R1

The incidence of acute respiratory infection in Indonesian infants and association with vitamin D deficiency

Dear Dr. Oktaria:

I'm pleased to inform you that your manuscript has been deemed suitable for publication in PLOS ONE. Congratulations! Your manuscript is now with our production department.

If your institution or institutions have a press office, please let them know about your upcoming paper now to help maximize its impact. If they'll be preparing press materials, please inform our press team within the next 48 hours. Your manuscript will remain under strict press embargo until 2 pm Eastern Time on the date of publication. For more information please contact onepress@plos.org.

If we can help with anything else, please email us at plosone@plos.org.

Thank you for submitting your work to PLOS ONE and supporting open access.

Kind regards,

PLOS ONE Editorial Office Staff

on behalf of

Dr. Pal Bela Szecsi

Academic Editor

PLOS ONE

Associated Data

    This section collects any data citations, data availability statements, or supplementary materials included in this article.

    Supplementary Materials

    S1 File. Study questionnaire and case report files.

    (PDF)

    Attachment

    Submitted filename: Review Comments.docx

    Attachment

    Submitted filename: review_Oktaria_et_al_PONE-D-20-33592_24_Dec_2020.docx

    Attachment

    Submitted filename: Response to the reviewers.docx

    Data Availability Statement

    The data underlying this study are available on Figshare (DOI: 10.6084/m9.figshare.13726525).


    Articles from PLoS ONE are provided here courtesy of PLOS

    RESOURCES